Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA) has accepted for review the marketing application for HSK39297, an oral small molecule inhibitor of complement factor B (FB), for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The candidate represents a next-generation alternative pathway inhibitor with demonstrated advantages over standard-of-care eculizumab in anemia improvement and transfusion reduction, while offering the convenience of oral administration.
Regulatory Milestone
Item
Detail
Agency
NMPA (China)
Filing Type
Marketing authorization application (NDA)
Product
HSK39297 (small molecule)
Target
Complement factor B (FB) – alternative pathway inhibitor
Indication
Paroxysmal nocturnal hemoglobinuria (PNH)
Developer
Haisco Pharmaceutical (SHE: 002653)
Filing Acceptance
March 2026
Review Timeline
Priority review potential given unmet need; decision anticipated Q4 2026
Drug Profile & Mechanism
Attribute
HSK39297 Profile
Drug Class
Small molecule complement factor B inhibitor
Mechanism
Blocks alternative pathway (AP) activation and complement amplification loop by inhibiting FB activity
Pathway Impact
Suppresses entire complement cascade at the amplification nexus
Route
Oral administration (vs. IV eculizumab)
Key Advantage
Convenience; potential for improved compliance and quality of life
Therapeutic Differentiation vs. Eculizumab:
Endpoint
HSK39297
Eculizumab (Standard of Care)
Clinical Advantage
Anemia Improvement
Notable therapeutic advantage
Moderate
Superior hemoglobin recovery
Transfusion Requirements
Significant reduction
Partial reduction
Greater transfusion independence
Fatigue Symptoms
Marked alleviation
Variable
Enhanced patient-reported outcomes
Efficacy Durability
Potentially maintainable long-term
Requires ongoing IV infusions
Sustained benefit with oral dosing
Subgroup Efficacy
Consistent across age, gender, disease duration, baseline hemoglobin
Variable response
Broad patient population benefit
Pipeline Expansion & Franchise Strategy
Indication
Study Phase
Status
Strategic Value
PNH
NDA under review
NMPA filing accepted
Near-term revenue catalyst; proof-of-concept for complement platform
Lupus Nephritis
Phase II
Ongoing
Large autoimmune market; potential best-in-class oral alternative to belimumab
Primary IgA Nephropathy
Phase III
Initiating
High unmet need; complement inhibition validated by iptacopan approval
Market Context & Competitive Landscape
Factor
Market Implication
PNH Market Size
Global market ~$3-4 billion; China represents fastest-growing segment with improving diagnosis rates
Novartis’ iptacopan (Factor B inhibitor, approved 2023) first oral entrant; Haisco targets China market leadership
Differentiation
HSK39297 demonstrated superior anemia outcomes vs. eculizumab in head-to-head comparisons; pricing power potential
Pipeline Synergy
Factor B platform applicable across multiple complement-mediated diseases (GN, aHUS, AMD)
Strategic Outlook
China Launch: 2027 commercialization anticipated; NRDL negotiation for national reimbursement
Global Ambitions: U.S./EU filing preparation ongoing; potential for FDA Fast Track based on China data package
Platform Value: Oral complement inhibition addresses IV therapy burden; HSK39297 validates Haisco’s immunology drug discovery capabilities
Manufacturing: Integrated small molecule capacity supports commercial supply and cost competitiveness
Forward‑Looking Statements This brief contains forward‑looking statements regarding regulatory approval timelines, commercial launch, and pipeline expansion for HSK39297. Actual results may differ due to NMPA review decisions, competitive dynamics with iptacopan, and pricing negotiations.-Fineline Info & Tech
By Fineline Cube